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The efficacy of acetylcholinesterase inhibitors and memantine in the symptomatic treatment of 
Alzheimer’s Disease is well-established. Randomised trials have shown them to associate with a 
reduction in the rate of cognitive decline. The aim of this study was to investigate the real-world 
effectiveness of acetylcholinesterase inhibitors and memantine for dementia causing diseases in the 
largest UK observational secondary care service dataset to date. 
Methods 
We extracted mentions of relevant medications and cognitive testing (Mini-Mental State 
Examination - MMSE and Montreal Cognitive Assessment - MOCA scores) from de-identified patient 
records from two NHS Trusts. The 10-year changes of cognitive performance were modelled using a 
combination of generalized additive and linear mixed-effect modelling. 
Results 
We found that the initial decline in MMSE and MOCA scores occurs approximately 2 years before 
medication is initiated. Medication prescription stabilises cognitive performance  for the ensuing 2 
to 5 months. The effect is boosted in more cognitively impaired cases at the point of medication 
prescription and attenuated in those taking antipsychotics. Importantly, we identify that patients 
who switch at least once between agents do not experience any beneficial cognitive effect from 
pharmacological treatment.  
Conclusion 
This study presents the largest real-world examination of the efficacy of acetylcholinesterase 
inhibitors and memantine for symptomatic treatment of dementia. We found evidence that 68% of 
individuals respond to treatment with a period of cognitive stabilisation before continuing their 
decline at the pre-treatment rate.  
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The evidence for cholinergic loss in dementia1,2 that correlates with severity of disease informed the 
development of a class of drugs that inhibit the enzyme acetylcholinesterase thus increasing the 
neuronal availability of acetylcholine. Three acetylcholinesterase inhibitor (AChEI) agents have been 
approved (donepezil, rivastigmine and galantamine) for the treatment of mild to moderate forms of 
Alzheimer’s disease (AD)3–5. Memantine is the fourth available option which is thought to counteract 
some of the neurotoxicity in AD through antagonism of the glutamate NMDA receptor6. In contrast 
to AChEIs, memantine is approved for the treatment of the more advanced forms of AD4,7,8.  
The currently approved symptomatic treatment for AD rests on evidence from randomised clinical 
trials (RCTs) showing an effect of stabilising cognitive decline or marginally improving cognitive 
function for a period of 3 to 6 months before typically the patients resume their cognitive 
deterioration. Besides cognition, these medications often associate with improvements in global 
functioning, behavioural and psychological symptoms of AD and benefit quality of daily activities in 
patients3. Efficacy over the neuropsychiatric symptoms of AD may underlie the observation that 
withdrawal of these medications in the severe stages of the disease associates with a higher risk of 
placement into institutionalised care5. The symptomatic benefits of these medications associate with 
disease severity, as patients with moderate to severe AD tend to benefit more in comparison to the 
mild cases9,10. Response rates reportedly vary between 20% and 60%, depending on medication 
dosage, socio-demographical factors (e.g. education and lifestyle) as well as presumed dementia 
etiology4,7,8.  
While RCTs are the gold standard when investigating the effects of an intervention, they only 
provide information on how well the intervention performs in an ideal clinical circumstance 
(‘efficacy’). The frequently unattainable information is how well the medication performs in real-
world conditions where a number of confounding factors are at play (‘effectiveness’)11. A notable 
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instance of an investigation into AChEI effectiveness reported it to be similar to clinical trial settings, 
whereby patients stabilise cognitively for a period of 6 months after the medication prescription12.  
We sought to provide further evidence for the real-world effectiveness of AChEIs as well as 
memantine on cognition in patients with varying severity of dementia. We used the UK-CRIS system 
which transforms routinely collected clinical data into a pseudonymised resource, to study relevant 
medical data from two UK National Health Service (NHS) Trusts. We hypothesised that we would 
replicate the observation that both AChEIs and memantine associate with a temporary stabilisation 
in the cognitive decline of up to 6-month duration that is predicted by severity of disease (better 
effectiveness in moderate-to-severe AD), type of dementia (better effectiveness in AD and mixed 
dementia compared to other forms), age (worse cognitive outcomes with older age), effect of other 
medication (worse effectiveness on patients that receive antipsychotics). We also hypothesised that 
a sub-group of primary non-responders would be evident and that they would be characterised by 
medication switches and will be associated with worse cognitive outcomes.  
Method 
Data sources 
We used the electronic patient records of two UK Mental Health NHS Trusts (Oxford Health and 
Southern Health NHS Foundation Trusts, OHFT and SHFT respectively). The data is accessible through 
the UK- Clinical Record Interactive Search system (UK-CRIS) which provides means of analysing de-
identified secondary care clinical case records from 12 UK Mental Health NHS Trusts 
(https://crisnetwork.co/). UK-CRIS allows access to structured information, such as diagnoses (i.e. 
International Classification of Disease 10th revision, ICD-10, codes) and demographic information, as 
well as unstructured text information, e.g. clinical notes. The data sources contain rich free-text 
information on the history of the mental health disorders under treatment, relevant cognitive and 
other structured assessments, medication treatments and other clinically relevant information. We 
included in our analysis patient records that featured a diagnosis of dementia through either 
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structured ICD-10 codes or mentions of dementia diagnosis in the clinical notes. The pool of records 
used in the study consisted of 24,108 patients that collectively contributed more than 3,700,000 
individual clinical documents. To extract the information from the free text, we developed a natural 
language processing (NLP) model that extracts any mentions of diagnosis, medication and cognitive 
health assessments (Mini-Mental State Examination (MMSE13) and Montreal Cognitive Assessment 
(MOCA14)). For more information on the model and accuracy of extractions, please see the 
supplemental materials (i.e. Table S1 and S2). The final structured data used in the study consisted 
of 7,415 patients diagnosed with dementia with 23,794 MMSE scores and 4,187 patients with 8,873 
MOCA scores (for descriptive statistics see supplementary materials).  
We assert that all procedures contributing to this work comply with the ethical standards of the 
relevant national and institutional committees on human experimentation and with the Helsinki 
Declaration of 1975, as revised in 2008. The study was approved by the local UK-CRIS oversight 
committees and is covered by approval for the UK-CRIS database granted by the Oxfordshire and 
Southern Health Research Ethics Committee. Individual patient consent was not required for the use 
of anonymised data. The data used in the study can be accessed using the UK-CRIS environment 
after receiving research approvals from the relevant UK-CRIS oversight bodies. The R code for the 
analysis and the NLP model can be download from the Open Science Framework page (see 
https://osf.io/4xev5/).  
Data Analysis 
The data was analysed using Generalized Additive Mixed-effect Modelling (GAMM)15. GAMM is a 
data-driven method designed to estimate the nonlinear relation between numeric predictors and 
dependent variables16. This method enabled study of nonlinear changes in cognitive performance 
across the time of disease, as well as periods when cognitive ability stabilises or starts to decline.  
We used a GAMM model to analyse and describe the nonlinear temporal changes in cognitive scale 
scores (MMSE and MOCA) in relation to the time point of medication prescription as well as the 
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modulating effects of switching between drugs. The random structure was adjusted in each model, 
whereby we included by-patient random intercepts. In other words, the model allowed intercepts to 
vary for each patient, additionally specifying patient factor as a source of variation in the data17,18. All 
models reported in the study are adjusted for age at cognitive assessment, gender, and duration of 
dementia. Ethnicity and marital status information was not accounted for as there was a large 
amount of missing data and not enough variation. The main model was fitted on the joint data from 
the two NHS Trusts (for Trust specific analysis see supporting materials) and we separated the 
analysis based on MMSE and MOCA scores. Due to the smaller number of observations for the 
MOCA scores, for subgroup analyses we focused only on the MMSE scores. We tested nonlinear 
changes of cognitive performance dependent on the MMSE score at the moment of medication 
prescription, dividing patients into four groups: normative decline (30 to 25 MMSE points), mild (24 
to 20 MMSE points), moderate (20 to 13 MMSE points) and severe cognitive impairment groups (12 
points or less). We calculated the periods of statistically significant changes in the slope of the 
nonlinear function, that is, significant stabilisation or improvement in cognition as measured by 
cognitive tests. These periods of change in trajectory can provide information on the duration of any 
observed medication-induced stabilisation in cognitive performance. Besides estimating the overall 
shape of the function, we also sought to characterise the cognitive trajectories of responders and 
non-responders to medication. Firstly, we investigated the change in MMSE scores for patients that 
either switched between medications or received monotherapy throughout. Secondly, to calculate 
the percentage of responders, we looked at the patients that had at least two observation of MMSE 
scores taken in the period of 6 months before and after the medication was prescribed, and then 
calculated the raw change in MMSE between these two measurements. A summary table for all 
main variables is included in the supplemental materials (see Table S3). 
To investigate the intermediary effects of individual predictors on the slope of the cognitive declines, 
we used linear mixed-effect models as implemented in the lme4 package in R19. Similar to the 
GAMMs, linear mixed-effect models allow modelling of repeated measures contributed by 
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numerous patients while quantifying effects of predictors on cognitive changes across the time. Even 
though these models are not developed to answer questions regarding nonlinearities and time 
changes, adding complex interactions to GAMM model can overfit the data, due to the relatively 
small sample sizes in subcategories of factors. For the same reason, the linear mixed-effect models 
were fitted only on MMSE scores using the combined OHFT and SHFT dataset. We utilised these 
models by fitting linear functions on subsets of the data, defined in relation to the time point of 
medication prescription (i.e. before medication prescription, first five months of medication, and 
effects beyond 5 months). Using this approach, we examined whether factors of interest influence 
stages of disease differently, especially in terms of short- and long-term effects of medication. Linear 
models were used to test the modifying effects of severity and presumed dementia aetiology, as 
well as, type of medication, concomitant medications (e.g. antipsychotics, antidepressants or 
diabetes-related medication), and gender on the positive effects of medication using interaction 
terms. We also included cognitive impairment (MMSE at prescription) severity as a predictor in the 
model.  
The standard estimation of the parameters in the linear mixed-effect analysis is a comparison 
between the factor combinations used in the experiment. The analysis utilises standard dummy 
coding of categorical predictors to estimate the regression coefficients. Specifically, one level for 
each factor is chosen to serve as a referential level against which all other levels and their 





Effectiveness of Medication on Cognitive Scale Scores (MMSE and MOCA Scores) 
We found that MMSE scores change in a non-linear fashion relative to the time point of medication 
prescription. In the three-year period prior to medication prescription patients scored in the region 
of 28 MMSE points and remained broadly cognitively stable. Approximately two years before 
medication was prescribed, a statistically significant decline in cognitive performance, i.e. MMSE 
scores, was evident. The decline in MMSE scores lasted up to the moment when the medication was 
prescribed at which point a stabilisation in cognitive change occurred (see Figure 1).  This period of 
statistically significant stability period lasted on average for 4 months, ranging from 2  to 5 months, 
OHFT and SHFT data respectively (see Figure S4 and S5 in supplementary materials; nonlinear effect 
of age and time since diagnosis is presented in Figures S2 and S3). After this period of stabilisation,  
the cognitive decline continued at the rate prior to symptomatic treatment initiation.  
INSERT FIGURE 1 
A split by cognitive impairment severity, defined by MMSE score at medication prescription time, 
shows that patients with severe deficits tended to benefit more from medication (see Figure 1B). 
Patients that scored between 25 to 30 MMSE points, started to decline almost immediately after 
starting the medication (Figure 1C). Patients with mild deficits (MMSE 20-24) stabilise in their 
cognition for a period of 4 months post-treatment initiation (Figure 1D), while the ones with a 
moderate degree of impairment (MMSE 13-20, Figure 1E) stabilise for a period of 10 months. Finally, 
patients with severe deficits (MMSE scores <12, Figure S5D) also experience a period of stabilisation 
in terms of cognitive decline, but the analysis is limited by the small number of observations. An 
identical effect was observed when we used MOCA instead of MMSE scores as an outcome measure 




Effect of Medication Switch 
In the second step of the analysis, we examined how the observed medication effect is dependent 
on whether patients were switched between agents or remained on monotherapy. The 
monotherapy group was defined as patients who were prescribed only one AChEi or switched to 
memantine in their records. This group was sought as a type of medication pathway that resembles 
suggestions from the NICE guidelines, that is, patients were prescribed one of the AChEis and, once 
benefits subsided, they were switched to memantine. The switch group were all patients that 
switched between symptomatic agents or took a combination of memantine and AChEIs. Contrary to 
the monotherapy group, these medication pathways might indicate treatments that diverge from 
the NICE guidelines. The majority of patients were treated with monotherapy (6,062 patients or 81% 
of the datasets, contributing 16,929 MMSE scores or 71% of the dataset) with the remainder (1,353 
patients or 19% contributing 6,865 MMSE measures or 29% of the dataset) switching at least once to 
a different symptomatic agent. Our results indicate differences in the duration of disease  between 
monotherapy patients (M = 350 days, SD= 480) and medication switch group (M = 657 days, SD = 
527; t(1893,8) = -19.66, p < .001). However, we also observed that those receiving monotherapy 
experience benefits from the medication in the form of stabilisation in cognitive performance for 
approximately 5 months after medication prescription (Figure 2A). Those who switched at least once 
tended to continue to decline at their pre-medication rate thus not benefiting from such 
pharmacological interventions (Figure 2B). This effect persists after controlling for the duration of 
the disease in the model.  
INSERT FIGURE 2 
We went on to investigate the proportion of patients who could be defined as responders versus 
those that were non-responders. As described earlier, we focused on patients with at least two 
MMSE measurements, allowing calculation of raw the MMSE score change between the 6 months 
pre-prescription versus the 6-month period post-prescription. Using this method, we identified 1521 
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patients with 68% defined as responders (29% increased their cognitive score and 39% had 
stabilisation of scores). Respectively, 32% continued their decline in cognitive performance from 
their pre-treatment score.  
Predictors of Response to Treatment 
Pre-Medication Period  
During the pre-medication period age and gender were significant predictors of cognitive scores. 
Specifically, older age (β = -0.03, SE = 0.01, t-value = -2.97, p <.01) and gender (βmale = 0.50, SE = 0.15, 
t-value = 3.38, p <.001) were associated with lower MMSE score, while over time (prior to 
medication) the patients declined in their cognitive performance (β = -1.26, SE = 0.06, t-value = -
18.6, p <.001).  
Immediate Effectiveness (First 5 months) 
During the first 5 months of medication prescription, we observed significant effects on cognitive 
performance from the gender factor (poorer outcome in females) but not age. Patients that received 
memantine or that discontinued medication had a steeper decline in MMSE scores than patients 
receiving symptomatic treatment continuously. More significant cognitive impairment, indicated by 
lower MMSE score at the time of medication prescription, was associated with significantly lower 
MMSE scores at the end of the 5 months. The severity of impairment and concomitant medications 
affect the slope of MMSE changes and interact with the effectiveness of symptomatic dementia 
treatment. Patients with more severe forms of the disease tended to benefit more from medication. 
Specifically, patients with observation in the normal range of MMSE score at the time of medication 
prescription (25-30) did not seem to benefit from the medication (MMSE Slope = -3.21). Patients 
with mild deficits (20-24 MMSE points) saw an increase in MMSE scores (Slope + Slope x SeverityMild 
= 0.7 MMSE points increase per year), while the patients with a moderate and severe degree of 
cognitive impairment experienced an increase in their MMSE score of 3.49 and 5.77 MMSE points in 
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a year respectively. Similar effects are observed for patients that received antipsychotic medication 
at any time point. Specifically, patients with concomitant antipsychotic medication do not benefit 
from receiving dementia-related medication, but rather they tend to decline stronger in their 
cognitive performance (Table 1). 
INSERT TABLE 1 
Longer-Term Effectiveness (5 months to 4 years) 
During the longer-term period post prescription, patients continued declining in their cognitive 
performance at a rate consistent with their pre-medication cognitive trajectory (slope of MMSE 
changes was -1.15 per year). Age and time since diagnosis were significant factors: older age was 
associated with slightly higher MMSE scores, while a longer period since being diagnosed with 
dementia associated with lower MMSE scores. The same held true for patients treated with 
memantine or discontinuing treatment versus patients who were prescribed AChEIs throughout. 
Presumed aetiology of dementia and gender did not reach statistical significance, while the severity 
of cognitive impairment, defined as the MMSE score at medication prescription, was significant. In 
other words, patients with lower initial MMSE score, had on average lower scores, while the change 
of MMSE scores across the time did not differ between the groups. Finally, patients that received 
antipsychotic-related medication during their treatment tended to have lower average MMSE scores 
and declined more steeply over time in comparison to patients who did not receive this class of 
medication. Antidepressants and diabetes medication were not significant factors in the models.  
INSERT TABLE 2 
Discussion and conclusion 
The efficacy of AChEIs and memantine is well established, whereby previous studies have shown a 
short-term stabilisation of cognitive decline in AD3,5. However, the performance of such medications 
is rarely assessed in real-world settings where several confounders can modify the expected 
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effects11. In this study, we utilised the UK-CRIS system to investigate the effectiveness of 
symptomatic pharmacological treatment of cognitive deficits in dementia causing diseases. 
Electronic health records represent an ideal environment to investigate the extent to which the 
effectiveness of treatments coincides with efficacy derived from randomised clinical trials. Using 
secondary care data from two UK Mental Health NHS Trusts, we were able to demonstrate that the 
beneficial effects of cholinesterase inhibitors and memantine are also observed in the real-world 
conditions.  
Our analysis illustrates 10-year changes in cognitive performance as measured by the MMSE and 
MOCA scales. The results show that the first significant evidence for cognitive decline becomes 
observable approximately 2 years before medication prescription. Once the medication gets 
prescribed, the patients tend to stabilise cognitively for the ensuing 4 months. Our study also shows 
that the beneficial effect of medications differs between the two NHS Trusts, whereby SHFT patients 
had a longer period of cognitive stabilisation (5 months) as opposed to the OHFT cohort (2 months). 
A potential reason for this is the larger sample size of the SHFT relative to OHFT data. More 
importantly, the SHFT Trust has more patients that are followed throughout the disease course, 
whereby it contributes twice the number of cases with over 5 observations per patient in 
comparison to OHFT (see descriptive statistics in supplemental materials). Therefore, the longer 
duration of stabilisation observed in the SHFT is likely to be a closer estimate of the real-world 
effectiveness of these drugs.  
The MMSE results are also replicated when the MOCA scale is used. We observed that the patients 
were starting to decline 1 year and 8 months before initial medication prescription. Similar to the 
MMSE analysis, once the medication is prescribed there is an observable period of stabilisation of 
cognitive performance lasting approximately 7 months.  MOCA is known to be more sensitive to 
subtler cognitive deficits than MMSE and is often used to detect a transition from normal cognition 
to mild cognitive impairment20. The MMSE test, on the other hand, better captures changes from 
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moderate to severe degrees of cognitive impairment20. Given that the main difference between the 
two tests is the larger emphasis on executive function in MOCA, it may therefore be that the longer 
period of stabilisation with treatment observable with MOCA relative to MMSE indicates that these 
medications benefit preferentially neural networks underpinning this cognitive domain.  
Not all patients benefit from treatment and our study estimates that approximately a third (32%) 
can be classed as primary non-responders. We show that medication switches are a sensitive 
approach to distinguishing responders from non-responders, whereby patients that make at least 
one medication switch tend to receive less or no benefits at all. In contrast, patients who remain on 
monotherapy tend to respond better and stabilise in their cognitive changes for a period once the 
medication is prescribed. Importantly, the proportion of responders identified in this real-world 
dataset is higher than the rate identified in clinical trials and prospective cohorts (68% in our analysis 
vs 40% in other analyses) which increases the confidence in the rationale for prescribing such 
medications9,21. One potential reason for this discrepancy is the unmeasured placebo effect of 
medication. Increase in support of dementia treatment that patients receive once prescribed 
medication or diagnosed with the disease might lead to improvements in cognitive performance.  
Analysis of the impact of concomitant medications shows a significant influence of antipsychotics on 
cognitive trajectories, whereby patients prescribed this medication class do not stabilise or improve 
in their cognitive performance. This effect is in line with previous studies indicating worse 
effectiveness of symptomatic treatment of cognitive deficits in dementia in patients that receive 
antipsychotics12. We extend previous studies by showing that this effect continues throughout the 
disease course as these patients both have lower cognitive scores at AChEI/memantine prescription 
and experience a steeper cognitive decline thereafter.  
The degree of cognitive impairment at the time point of medication prescription attests as an 
equally important factor. We found that once the medication is prescribed, patients with lower 
MMSE scores respond much better. Patients with MMSE scores in the normal range continue to 
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decline cognitively despite being prescribed symptomatic treatment, while patients with a mild 
degree of impairment stabilise in their cognitive performance4,10. The effect is even stronger with 
lower MMSE scores at baseline, as patients with a moderate and severe degree of impairment 
experience an improvement in their cognitive performance12. However, the group of patients with 
severe impairment in our dataset was significantly smaller in comparison to all other groups. We 
found that these patients are not re-assessed cognitively as frequently after medication prescription 
relative to the milder impairment groups and therefore these results require cautious interpretation.  
Our study also showed that individuals on memantine have worse cognitive outcomes. This is 
unsurprising as the UK NICE guidelines recommend memantine for moderate-to-severe AD and 
AChEIs for the mild-to-moderate forms22. The guidance also states that treatment should start with 
the drug that has the lowest acquisition costs, resulting in donepezil being often the first choice of 
medication prescription. This is also illustrated in the case of our extracted NHS Trust data, whereby 
most of the patients recorded in the system received donepezil (57% in SHFT and 62% in OHFT data).  
Our study illustrates the feasibility of using electronic health records to investigate the effectiveness 
of cognitive enhancers in dementia. There are however several limitations. The extracted 
observational data does not allow the direct comparison between medications, as we cannot 
randomly assign patients to treatments. This is exacerbated when we take into account the 
heterogeneity of factors that influence patient outcomes. In particular, this study is not able to 
provide sufficient depth of information on the impact of concomitant medication that may impact 
cognition (e.g. anticholinergics24) beyond antidepressants and antipsychotics due to the pattern of 
an inconsistent or missing recording of GP-initiated in secondary mental health records. An 
additional factor that our analysis was not able to differentiate was the potential impact of the level 
of informal and formal (i.e. Community Mental Health Team coordination, Social Services Package of 
Care) support that patients may have received, which could be one of the multiple factors that 
drives differences between two NHS Trusts. Additionally, our automated NLP model extracted 
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generally well the concepts of interest, reaching around 90% of accuracy (see supplementary 
materials). However, this accuracy decreases with certain categories (experiencer or modality 
subcategories) and increases the noise in the data.  
Beyond these limitations, we show that the combination of NLP and statistical models provides an 
unprecedented opportunity to examine large real-world datasets to estimate how well RCT reported 
efficacy translates into effectiveness. Finally, we believe that our paper has direct relevance to 
clinical practice, providing clinicians with a likelihood for the expected response and its expected 
duration in real-world settings (cognitive stabilisation for up to 4 months in about two-thirds of 
patients) to guide discussions with patients and family. It may also serve to steer debate concerning 
the value of switching to alternative cognitive enhancers on the basis of lack of efficacy of the initial 
therapy as well as the value of antipsychotic prescription in dementia given evidence for deleterious 
cognitive effects.    
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